Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Avalanche Treasury Corporation Class A Common Stock (AVAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Avalanche Treasury Corporation Class A Common Stock — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $287.7 (market cap $39.89B), while Avalanche Treasury Corporation Class A Common Stock trades at $0.52 (market cap $21.30M). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 1872.8× Avalanche Treasury Corporation Class A Common Stock's market cap. Which is the better fit depends on your goals.
| ALNY | AVAT | |
|---|---|---|
Market Cap | $39.89B | $21.30M |
Sector | Health | Financials |
52-Week High | $491.22 | $10.75 |
52-Week Low | $278.09 | $0.51 |
Enterprise Value | $38.15B | $21.30M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
AVAT trades at $0.54, down 6.9% in the past 24 hours, with a bearish technical signal driven by moving averages. The company reported a net income of $8.28 million for 2025, but cash flow from operations was negative $930,710. Recent news highlights its Nasdaq listing, positioning it as an operating company focused on capital allocation within its ecosystem.
The outlook is mixed: low P/E of 12 and P/B of 0.4 suggest potential value, but negative operating cash flow and a bearish technical trend pose risks. Investor sentiment is cautious amid recent volatility, with institutional interest pending further financial stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Avalanche Treasury Corporation Class A Common Stock
Avalanche Treasury Corp operates as a digital asset treasury company focused on holding and managing digital asset investments. The company was founded on September 22, 2025, and is headquartered in New York, NY.
Read more on AVAT →
